Abstract
Tacrolimus has long been the cornerstone of the immunosuppressive standard-of-care in kidney transplantation. Until recently, only an immediate-release formulation of tacrolimus was available in the clinic for twice-daily administration, a schedule that is known to hamper prescription adherence and contributes to the already significant tacrolimus interactions with other drugs and meals. In order to improve patient compliance, two once-daily prolonged-release formulations of tacrolimus have recently been developed and approved. Here we will analyze the main characteristics of these two prolonged-release formulations with the aim to provide practical clinical information for a fully aware drug prescription. Finally, the theoretical advantages of the prolonged-release formulations in terms of prescription adherence, blood level steadiness and drug efficacy and tolerability will be critically reviewed, in order to define the profile of renal recipients who may benefit most from the switch to once-daily tacrolimus.
Similar content being viewed by others
References
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155. doi:10.1111/j.1600-6143.2009.02834.x
Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357(25):2562–2575
Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331(7520):810
Hart A, Smith JM, Skeans MA et al (2016) OPTN/SRTR annual data report 2014. Am J Transplant 16(S2):11–46. doi:10.1111/ajt.13666 (Special Issue)
Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351(26):2715–2729
Provenzani A, Santeusanio A, Mathis E et al (2013) Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 19(48):9156–9173. doi:10.3748/wjg.v19.i48.9156
Grinyó JM, Petruzzelli S (2014) Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol. 10(12):1567–1579. doi:10.1586/1744666X.2014.983903
Garnock-Jones KP (2015) Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients. Drugs 75(3):309–320. doi:10.1007/s40265-015-0349-2
www.fda.gov/downloads/Drug/GuidanceComplianceRegulatoryInformation/Guidance/UCM181006.pdf. Accessed 16 Mar 2016
Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43(10):623–653
Prograf (2013) Prescribing information. Astellas Pharma US, Inc; Northbrook
Ekberg H, Bernasconi C, Tedesco-Silva H et al (2009) Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 9(8):1876–1885. doi:10.1111/j.1600-6143.2009.02726.x
Malvezzi P, Rostaing L (2015) The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf 14(10):1531–1546. doi:10.1517/14740338.2015.1083974
Cippà PE, Schiesser M, Ekberg H et al (2015) Risk stratification for rejection and infection after kidney transplantation. Clin J Am Soc Nephrol 10(12):2213–2220. doi:10.2215/CJN.01790215
Vanhove T, Annaert P, Kuypers DR (2016) Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48(1):88–112. doi:10.3109/03602532.2016.1151037
Paine MF, Khalighi M, Fisher JM et al (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283(3):1552–1562
Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K (2004) Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther 75(4):352–361
Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41(11):813–851
Nowack R (2008) Herb-drug interactions in nephrology: documented and theoretical. Clin Nephrol 69(5):319–325
Bekersky I, Dressler D, Mekki QA (2001) Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 41(2):176–182
Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H Jr, Medina-Pestana JO (2007) Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol 21(2):191–197
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000712/WC500022237.pdf. Accessed 16 Mar 2016
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000712/WC500022234.pdf. Accessed 16 Mar 2016
MeltDose® Technology by the US Patent and Trademark Office. US7217431
Nigro V, Glicklich A, Weinberg J (2013) Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 Hrs: a scintigraphic and pharmacokinetic evaluation. Am J Transplant. Poster, Abstract# B1034
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002655/WC500170412.pdf. Accessed 16 Mar 2016
Staatz CE, Tett SE (2015) Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin Pharmacokinet 54(10):993–1025. doi:10.1007/s40262-015-0282-2
de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y (2010) Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 90(5):523–529. doi:10.1097/TP.0b013e3181e9feda
Wu MJ, Cheng CY, Chen CH et al (2011) Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 92(6):648–652. doi:10.1097/TP.0b013e3182292426
Hougardy JM, Broeders N, Kianda M et al (2011) Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 91(5):566–569. doi:10.1097/TP.0b013e3182098ff0
Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S (2013) Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 96(2):191–197. doi:10.1097/TP.0b013e3182962cc1
Alloway RR, Eckhoff DE, Washburn WK, Teperman LW (2014) Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl 20(5):564–575. doi:10.1002/lt.23844
Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE (2011) Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs 71(12):1561–1577. doi:10.2165/11593890-000000000-00000
Alloway RR, Mulgaonkar S, Ueda D, et al (2011) A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro™ tablets once-a-day to Prograf® capsules twice-a-day in de novo kidney transplant patients. Am J Transplant. Poster, Abstratct #1106
Niioka T, Satoh S, Kagaya H et al (2012) Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 94(10):1013–1019. doi:10.1097/TP.0b013e31826bc400
Tsuchiya T, Ishida H, Tanabe T et al (2013) Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation 96(2):198–204. doi:10.1097/TP.0b013e318296c9d5
Stifft F, Stolk LM, Undre N, van Hooff JP, Christiaans MH (2014) Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation 97(7):775–780. doi:10.1097/01.TP.0000437561.31212.0e
Hardinger KL, Hutcherson T, Preston D, Murillo D (2012) Influence of pill burden and drug cost on renal function after transplantation. Pharmacot 32(5):427–432. doi:10.1002/j.1875-9114.2012.01032.x
Sellarés J, de Freitas DG, Mengel M et al (2012) Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12(2):388–399. doi:10.1111/j.1600-6143.2011.03840.x
Tielen M, van Exel J, Laging M et al (2014) Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant. doi:10.1155/2014/675301
Shuker N, van Gelder T, Hesselink DA (2015) Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev 9(2):78–84. doi:10.1016/j.trre.2015.01.002
Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. J Clin Ther 23(8):1296–1310
Obi Y, Ichimaru N, Kato T et al (2013) A single daily dose enhances the adherence to immunosuppressive treatment in kidney transplant recipients: a cross-sectional study. Clin Exp Nephrol. 17(2):310–315. doi:10.1007/s10157-012-0713-4
Kuypers DR, Peeters PC, Sennesael JJ et al (2013) Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 95(2):333–340. doi:10.1097/TP.0b013e3182725532
van Boekel GA, Kerkhofs CH, Hilbrands LB (2013) Treatment satisfaction in renal transplant patients taking tacrolimus once daily. Clin Ther 35(11):1821–1829. doi:10.1016/j.clinthera.2013.09.014
Singh N, Von Visger J, Zachariah M (2015) Extended release once a day tacrolimus. Curr Opin Organ Transplant. 20(6):657–662. doi:10.1097/MOT.0000000000000251
Butler JA, Peveler RC, Roderick P, Horne R, Mason JC (2004) Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 77(5):786–789
Muduma G, Shaw J, Hart WM, Odeyemi A, Odeyemi I (2014) Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Pat Pre Adher 8:1537–1546. doi:10.2147/PPA.S69461
Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC (2004) Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 4(4):621–625
Alloway R, Steinberg S, Khalil K et al (2005) Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 37(2):867–870
van Hooff J, Van der Walt I, Kallmeyer J et al (2012) Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 34(1):46–52. doi:10.1097/FTD.0b013e318244a7fd
Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T (2010) High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 25(8):2757–2763. doi:10.1093/ndt/gfq096
Revollo J (2015) Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Dev Ther 9:2581–2583. doi:10.2147/DDDT.S84301
Niioka T, Kagaya H, Miura M et al (2013) Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol 69(9):1659–1665. doi:10.1007/s00228-013-1514-8
Posadas Salas MA, Srinivas TR (2014) Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Dev Ther 8:1183–1194. doi:10.2147/DDDT.S55458
Silva HT Jr, Yang HC, Abouljoud M et al (2007) One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transpl 7(3):595–608
Silva HT Jr, Yang HC, Meier-Kriesche HU et al (2014) Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 97(6):636–641. doi:10.1097/01.TP.0000437669.93963.8E
Krämer BK, Charpentier B, Bäckman L et al (2010) Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 10(12):2632–2643. doi:10.1111/j.1600-6143.2010.03256.x
Han DJ, Park JB, Kim YS et al (2012) A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. Transpl Proc 44(1):115–117. doi:10.1016/j.transproceed.2011.12.070
Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N (2013) OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation 96(10):897–903. doi:10.1097/TP.0b013e3182a203bd
Bunnapradist S, Ciechanowski K, West-Thielke P et al (2013) Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transpl 13(3):760–769. doi:10.1111/ajt.12035
Budde K, Bunnapradist S, Grinyó JM et al (2014) Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transpl 14(12):2796–2806. doi:10.1111/ajt.12955
Rostaing L, Bunnapradist S, Grinyó JM et al (2016) Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis 67(4):648–659. doi:10.1053/j.ajkd.2015.10.024
Considine A, Tredger JM, Heneghan M et al (2015) Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. Liver Transpl 21(1):29–37. doi:10.1002/lt.24022
Adam R, Karam V, Delvart V et al (2015) Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant 15(5):1267–1282. doi:10.1111/ajt.13171
Uchida J, Kuwabara N, Machida Y et al (2012) Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. Transpl Proc 44(1):128–133. doi:10.1016/j.transproceed.2011.11.005
Uchida J, Iwai T, Kabei K et al (2014) Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients. Transpl Proc 46(2):532–536. doi:10.1016/j.transproceed.2013.11.146
Langone A, Steinberg SM, Gedaly R et al (2015) Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant 29(9):796–805. doi:10.1111/ctr.12581
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Giovanni Piotti reports receiving consultant fees from Chiesi Farmaceutici SPA as medical research physician for the development of the medical product Envarsus. Elena Cremaschi declares that she has no conflict of interest. Umberto Maggiore is an Advisory Board or has received lecture fees from Teva, Sandoz, Chiesi, Astellas, Novartis.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study formal consent is not required.
Rights and permissions
About this article
Cite this article
Piotti, G., Cremaschi, E. & Maggiore, U. Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. J Nephrol 30, 53–61 (2017). https://doi.org/10.1007/s40620-016-0316-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-016-0316-3